cat no | io1007
ioGlutamatergic Neurons GBA null/WT are opti‑ox™ precision reprogrammed glutamatergic neurons carrying a genetically engineered heterozygous knockout of the GBA gene encoding the glucocerebrosidase (GCase) enzyme. The cells offer a suitable model to study the molecular and cellular processes seen in Gaucher and Parkinson’s diseases.
Related disease model cells are coming soon with a heterozygous PRKN R275W or a homozygous PRKN R275W mutation. All can be used alongside their genetically matched control, ioGlutamatergic Neurons™.
Coming Soon
Register your interest, and we will notify you as soon as the product is available.
Make True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to investigate the impact of the mutation.
Scalable
With opti-ox technology, we can make billions of consistently reprogrammed cells, surpassing the demands of industrial workflows.
Quick
The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
Starting material
Human iPSC line
Karyotype
Normal (46, XY)
Seeding compatibility
6, 12, 24, 48, 96 & 384 well plates
Shipping info
Dry ice
Donor
Caucasian adult male (skin fibroblast)
Vial size
Small: >1 x 106 viable cells
Quality control
Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)
Differentiation method
opti-ox cellular reprogramming
Recommended seeding density
30,000 cells/cm2
User storage
LN2 or -150°C
Format
Cryopreserved cells
Genetic modification
Heterozygous frameshift mutation in exon 5 of the GBA gene
Applications
FTD research
Drug discovery and development
Disease modelling
Electrophysiological assays (MEA)
Co-culture studies
Product use
These cells are for research use only
Emmanouil Metzakopian | Vice President, Research and Development | bit.bio
Javier Conde-Vancells | Director Product Management | bit.bio
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | bit.bio
Dr Tony Oosterveen, et al.
bit.bio & Charles River Laboratories
2023
Mark Kotter | CEO and founder | bit.bio
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
Madeleine Garrett | Field Application Specialist | bit.bio
Laila Ritsma et al.
Charles River Laboratories & bit.bio
2022
Read this blog to find out how experts from across academia and industry are approaching the challenges of reproducibility of in vitro cell models as well as potential solutions.
Further your disease research by pairing our wild type cells with isogenic disease models.